# Halozyme Therapeutics

Source: https://onco.cc/companies/halozyme/  
OnCo record `halozyme` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Halozyme's recombinant hyaluronidase (ENHANZE) is what lets antibodies such as rituximab, trastuzumab and daratumumab be given as quick under-the-skin injections instead of long infusions; its own tumour-targeting version failed in pancreatic cancer.

## Summary

Halozyme Therapeutics, founded in 1998 in San Diego, licenses its ENHANZE drug-delivery technology, a recombinant human hyaluronidase that breaks down hyaluronan under the skin so large volumes of antibody can be injected subcutaneously; the subcutaneous forms of rituximab, trastuzumab, daratumumab, pertuzumab and atezolizumab rely on it. Its own PEGylated hyaluronidase PEGPH20, aimed at hyaluronan-rich pancreatic tumours, failed the phase 3 HALO-301 trial in 2019. ClinicalTrials.gov lists Halozyme as lead sponsor of that and other phase 3 trials.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Halozyme Therapeutics, Inc.; Halozyme
- Tags: ctgov-sponsor
- HQ: San Diego, CA
- Type: biotech
- Website: https://www.halozyme.com

## Sources

- Official website: https://www.halozyme.com
- ClinicalTrials.gov: trials led by Halozyme Therapeutics, Inc.: https://clinicaltrials.gov/search?lead=Halozyme%20Therapeutics%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q5643474

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Daratumumab](https://onco.cc/drugs/daratumumab/), [Rituximab](https://onco.cc/drugs/rituximab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/halozyme.json